Glenmark Pharmaceuticals reports strong revenue growth and expansion plans for dermatology and respiratory portfolios in ...

Glenmark Pharmaceuticals on Friday said its consolidated profit after tax stood at Rs 348 crore for the third quarter ended ...

Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and ...

Glenmark Pharmaceuticals reported a consolidated profit after tax of Rs 348 crore in Q3 FY25, driven by strong regional ...

Glenmark Pharmaceuticals reported a significant profit of Rs 348 crore for Q3 2024, rebounding from a Rs 351 crore loss in ...

Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY. Revenue ...

The company reported a loss of Rs 351 crore in the comparable quarter last year, hurt by sluggish sales in India and charges ...

EBITDA zoomed to ₹600.3 crore in the third quarter over a loss of ₹208.7 crore in the year-ago quarter.  Shares of Glenmark ...

India's Glenmark Pharmaceuticals reported third-quarter profit below estimates on Friday due to bleak U.S. demand for its long-term illness drugs.

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine ...

The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has revised the retail ...

Elara sees the ongoing weakness as an opportunity to buy into the pharma space, as it expects robust earnings growth ahead at ...